Astellas Shares New VEOZAH Insights at Annual Menopause Event
Astellas Shares New VEOZAH Insights at Annual Menopause Event
TOKYO — Astellas Pharma Inc. announced that its innovative treatment, VEOZAH™ (fezolinetant), will take center stage at the upcoming Annual Meeting of The Menopause Society. This prominent event will be held in Orlando, showcasing six Astellas-sponsored poster presentations focused on the real-world efficacy of this non-hormonal solution for managing moderate to severe vasomotor symptoms (VMS) associated with menopause.
Understanding Vasomotor Symptoms
Vasomotor symptoms, commonly manifested as hot flashes and night sweats, are experienced by many women during menopause. The presentations at the conference aim to delve deeper into these symptoms and their management. Astellas is committed to advancing the understanding of VEOZAH, aiming to provide valuable insights into how it can help women navigate this challenging phase.
Insights from the OPTION-VMS Study
The research presented will include crucial findings from the OPTION-VMS study, which focuses on real-world outcomes for women starting non-hormonal treatments. These analyses are expected to reveal changes in VMS management and work productivity for women initiating this therapy, showcasing Astellas' dedication to patient-centered care.
Presenting Comprehensive Data
Karla Martins, Executive Medical Director for Global Medical Affairs at Astellas, highlighted the importance of sharing new data at this prestigious meeting. “We are pleased to unveil detailed findings on fezolinetant, contributing further evidence of its effectiveness and safety as a treatment option for managing VMS due to menopause,” she stated. This underscores Astellas' mission to enhance the lives of women experiencing menopause-related symptoms.
Poster Presentations You Shouldn't Miss
During the Annual Meeting, attendees can look forward to six insightful poster presentations, which will include the following topics:
- Preliminary analysis from the OPTION-VMS study, assessing real-world applications of non-hormonal therapies for menopause-associated VMS.
- Impact of non-hormonal treatment on work productivity outcomes for affected women.
- A comparison of fezolinetant and its alternatives in treating menopause-related vasomotor symptoms.
- Healthcare resource utilization among women receiving fezolinetant treatment.
- Analysis of VMS experiences following treatment discontinuation in pivotal SKYLIGHT trials.
- Safety profile of fezolinetant in already medically complex populations.
A fascinating additional poster will explore perceptions of menopause and VMS treatments among non-Hispanic/Latino Black or African American women, highlighting the diverse impacts of these symptoms.
What to Expect at the Conference
The VEOZAH posters will be presented on Thursday evening, allowing for discussions and reflections on how these findings can reshape approaches to menopause treatment.
About OPTION-VMS
The OPTION-VMS study is an ongoing Phase IV observational study targeting women aged 40-75 dealing with VMS due to menopause. The primary focus is not only on symptom management but also on the comprehensive quality of life factors affected by menopause.
About Astellas
Astellas is dedicated to transforming innovative research into tangible health solutions for patients around the globe. With an emphasis on areas such as oncology and women's health, Astellas strives to meet the needs of patients through groundbreaking therapies backed by science.
Frequently Asked Questions
What is VEOZAH?
VEOZAH is a non-hormonal treatment designed to alleviate vasomotor symptoms associated with menopause.
What are vasomotor symptoms?
Vasomotor symptoms primarily include hot flashes and night sweats experienced by women during menopause.
Where will the Astellas presentations take place?
The presentations will be held during the Annual Meeting of The Menopause Society in Orlando.
What is the goal of the OPTION-VMS study?
The study aims to evaluate the effectiveness of non-hormonal therapies in treating menopause-related vasomotor symptoms among women in real-world settings.
How does Astellas contribute to women's health?
Astellas focuses on developing innovative healthcare solutions that address unmet medical needs in women's health, including menopause management.
About The Author
Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.